Dupixent drives sales advancement in Sanofi's first quarter
Sanofi generated almost EUR 10bn in total sales during the year’s first three months. The French pharmaceutical firm gives several reasons why, one of which is a 45.7 percent growth of blockbuster drug Dupixent.
by christopher due karlsson, translated by daniel pedersen
Thursday, French pharmaceutical firm Sanofi has publicized its financial figures for the first quarter of the year, reporting that total sales in the first three months came to EUR 9.7bn.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
England and Wales reject Leo Pharma's eczema drug
For subscribers
.jpg&w=384&q=75)
